FAP
MCID: ADN021
MIFTS: 70

Adenomatous Polyposis Coli (FAP) malady

Categories: Genetic diseases, Rare diseases, Neuronal diseases, Eye diseases, Gastrointestinal diseases, Skin diseases, Fetal diseases, Bone diseases

Aliases & Classifications for Adenomatous Polyposis Coli

Aliases & Descriptions for Adenomatous Polyposis Coli:

Name: Adenomatous Polyposis Coli 54 13 69
Gardner Syndrome 54 50 24 56 69
Brain Tumor-Polyposis Syndrome 2 54 29 69
Familial Adenomatous Polyposis 1 54 29
Familial Adenomatous Polyposis 56 66
Gardner's Syndrome 50 29
Fap 56 66
Polyposis Coli and Multiple Hard and Soft Tissue Tumors 50
Apc-Related Attenuated Familial Adenomatous Polyposis 56
Intestinal Polyposis, Osteomas, Sebaceous Cysts 50
Apc-Related Attenuated Familial Polyposis Coli 56
Colorectal Adenomatous Polyposis 56
Turcot Syndrome with Polyposis 56
Apc-Related Attenuated Fap 56
Familial Polyposis Coli 56
Gardners Syndrome 52
Apc-Related Afap 56

Characteristics:

Orphanet epidemiological data:

56
familial adenomatous polyposis
Inheritance: Autosomal dominant,Autosomal recessive; Prevalence: 1-9/100000 (Europe),1-5/10000 (Denmark),1-9/100000 (Denmark),1-9/100000 (Sweden),1-5/10000 (Finland),1-9/100000 (Finland),1-5/10000 (United Kingdom),1-9/100000 (United Kingdom),1-9/1000000 (Australia),1-9/100000 (Australia); Age of onset: Adult; Age of death: adult;
apc-related attenuated familial adenomatous polyposis
Inheritance: Autosomal dominant,Autosomal recessive;
turcot syndrome with polyposis
Inheritance: Autosomal dominant; Age of onset: All ages;

HPO:

32
adenomatous polyposis coli:
Inheritance autosomal dominant inheritance
Onset and clinical course variable expressivity


Classifications:



External Ids:

OMIM 54 175100
MESH via Orphanet 43 D011125 D005736
ICD10 via Orphanet 34 D12.6
UMLS via Orphanet 70 C0032580 C0017097

Summaries for Adenomatous Polyposis Coli

NIH Rare Diseases : 50 gardner syndrome is a form of familial adenomatous polyposis (fap) that is characterized by multiple colorectal polyps and various types of tumors, both benign (noncancerous) and malignant (cancerous). people affected by gardner syndrome have a high risk of developing colorectal cancer at an early age. they are also at an increased risk of developing other fap-related cancers, such as those of the small bowel, stomach, pancreas, thyroid, central nervous system, liver, bile ducts, and/or adrenal gland. other signs and symptoms of gardner syndrome include dental abnormalities; osteomas (benign bone growths); various skin abnormalities such as epidermoid cysts, fibromas (a benign tumor of the connective tissue), and lipomas; and desmoid tumors. it is caused by changes (mutations) in the apc gene and inherited in an autosomal dominant manner. although there is no cure for gardner syndrome, management options are available to reduce the risk of cancer. these may include high risk screening, prophylactic surgeries and/or certain types of medications. last updated: 1/14/2015

MalaCards based summary : Adenomatous Polyposis Coli, also known as gardner syndrome, is related to colorectal cancer and familial adenomatous polyposis, and has symptoms including multiple lipomas, colon cancer and multiple gastric polyps. An important gene associated with Adenomatous Polyposis Coli is APC (APC, WNT Signaling Pathway Regulator), and among its related pathways/superpathways are HIV Life Cycle and Glioma. The drugs Erythromycin and Celecoxib have been mentioned in the context of this disorder. Affiliated tissues include colon, skin and thyroid, and related phenotypes are Upregulation of Wnt/beta-catenin pathway after WNT3A stimulation and cardiovascular system

OMIM : 54 Familial adenomatous polyposis-1 is an autosomal dominant disorder characterized by predisposition to cancer. Affected... (175100) more...

UniProtKB/Swiss-Prot : 66 Familial adenomatous polyposis: A cancer predisposition syndrome characterized by adenomatous polyps of the colon and rectum, but also of upper gastrointestinal tract (ampullary, duodenal and gastric adenomas). This is a viciously premalignant disease with one or more polyps progressing through dysplasia to malignancy in untreated gene carriers with a median age at diagnosis of 40 years.

Wikipedia : 71 Adenomatous polyposis coli (APC) also known as deleted in polyposis 2.5 (DP2.5) is a protein that in... more...

Related Diseases for Adenomatous Polyposis Coli

Diseases related to Adenomatous Polyposis Coli via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 87)
id Related Disease Score Top Affiliating Genes
1 colorectal cancer 29.2 APC AXIN1 AXIN2 CDH1 CTNNB1 GSK3B
2 familial adenomatous polyposis 11.9
3 samson gardner syndrome 11.8
4 attenuated familial adenomatous polyposis 11.5
5 mismatch repair cancer syndrome 11.2
6 mutyh-associated polyposis 11.2
7 desmoid disease, hereditary 10.8
8 duodenum cancer 10.8
9 soft tissue sarcoma 10.8
10 colorectal adenomatous polyposis, autosomal recessive, with pilomatricomas 10.8
11 adenoma 10.4
12 breast cancer 10.3
13 macular degeneration, early-onset 10.3 APC CTNNB1
14 dfnb1 10.2 APC CTNNB1
15 hepatocellular adenoma 10.2
16 hepatocellular carcinoma 10.2
17 thyroiditis 10.2
18 squamous cell carcinoma 10.2
19 lung cancer 10.1
20 oral squamous cell carcinoma 10.1
21 colorectal adenoma 10.1
22 neuronitis 10.1
23 diabetes mellitus, noninsulin-dependent, 2 10.1 APC CTNNB1
24 autoimmune autonomic ganglionopathy 10.1 APC AXIN2
25 desmoid tumor 10.1
26 granulocytopenia 10.1 CDH1 CTNNB1
27 familial hypopituitarism 10.0 APC CDH1
28 ideomotor apraxia 10.0 APC CDH1 CTNNB1
29 multicentric papillary thyroid carcinoma 10.0 AXIN1 AXIN2 CTNNB1
30 ameloblastoma 10.0
31 colitis 10.0
32 retinoblastoma 10.0
33 hepatitis 10.0
34 ulcerative colitis 10.0
35 colorectal adenocarcinoma 9.8
36 hepatitis c 9.8
37 gastroduodenitis 9.8
38 parathyroid carcinoma 9.8
39 melanoma 9.8
40 lichen planus 9.8
41 basal cell carcinoma 9.8
42 adenocarcinoma 9.8
43 autism spectrum disorder 9.8
44 cerebritis 9.8
45 hepatitis c virus 9.8
46 lymphoma 9.8
47 choriocarcinoma 9.8
48 fibromatosis 9.8
49 cranial nerve palsy 9.8
50 oral lichen planus 9.8

Graphical network of the top 20 diseases related to Adenomatous Polyposis Coli:



Diseases related to Adenomatous Polyposis Coli

Symptoms & Phenotypes for Adenomatous Polyposis Coli

Symptoms by clinical synopsis from OMIM:

175100

Clinical features from OMIM:

175100

Human phenotypes related to Adenomatous Polyposis Coli:

56 32 (show all 30)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 multiple lipomas 56 32 Occasional (29-5%) HP:0001012
2 colon cancer 56 32 Frequent (79-30%) HP:0003003
3 multiple gastric polyps 56 32 Very frequent (99-80%) HP:0004394
4 duodenal polyposis 56 32 Very frequent (99-80%) HP:0004783
5 adenomatous colonic polyposis 56 32 Very frequent (99-80%) HP:0005227
6 odontoma 56 32 Occasional (29-5%) HP:0011068
7 increased number of teeth 56 32 Occasional (29-5%) HP:0011069
8 carious teeth 32 HP:0000670
9 neoplasm 56 Frequent (79-30%)
10 delayed eruption of teeth 56 Occasional (29-5%)
11 irregular hyperpigmentation 56 Occasional (29-5%)
12 fibroma 56 Occasional (29-5%)
13 neoplasm of the central nervous system 56 Occasional (29-5%)
14 sarcoma 56 Occasional (29-5%)
15 adrenocortical carcinoma 32 HP:0006744
16 adrenocortical adenoma 32 HP:0008256
17 keloids 32 HP:0010562
18 astrocytoma 32 HP:0009592
19 hepatoblastoma 32 HP:0002884
20 hyperpigmentation of the skin 32 HP:0000953
21 medulloblastoma 32 HP:0002885
22 papillary thyroid carcinoma 32 HP:0002895
23 desmoid tumors 32 HP:0100245
24 epidermal cyst 32 HP:0200040
25 duodenal adenocarcinoma 32 HP:0006771
26 fibroadenoma of the breast 32 HP:0010619
27 unerupted tooth 32 HP:0000706
28 osteoma 32 HP:0100246
29 small intestine carcinoid 32 HP:0006722
30 congenital hypertrophy of retinal pigment epithelium 32 HP:0007649

UMLS symptoms related to Adenomatous Polyposis Coli:


abdominal pain, diarrhea

GenomeRNAi Phenotypes related to Adenomatous Polyposis Coli according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Upregulation of Wnt/beta-catenin pathway after WNT3A stimulation GR00016-A 8.92 APC AXIN1 AXIN2 GSK3B

MGI Mouse Phenotypes related to Adenomatous Polyposis Coli:

44 (show all 12)
id Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.21 MYC SPATA13 AMER1 APC AXIN1 AXIN2
2 cellular MP:0005384 10.1 AMER1 APC APC2 AXIN1 AXIN2 CDH1
3 growth/size/body region MP:0005378 10.06 AMER1 APC APC2 AXIN1 AXIN2 CDH1
4 craniofacial MP:0005382 10.02 AMER1 APC AXIN1 AXIN2 CTNNB1 GSK3B
5 digestive/alimentary MP:0005381 10 APC AXIN1 CDH1 CTNNB1 GSK3B MYC
6 embryo MP:0005380 9.98 AMER1 APC AXIN1 AXIN2 CDH1 CTNNB1
7 limbs/digits/tail MP:0005371 9.85 MYC AMER1 APC AXIN1 AXIN2 CTNNB1
8 normal MP:0002873 9.76 APC AXIN1 AXIN2 CDH1 CTNNB1 GSK3B
9 no phenotypic analysis MP:0003012 9.73 APC AXIN2 CDH1 CTNNB1 GSK3B MYC
10 neoplasm MP:0002006 9.72 CDH1 CTNNB1 MYC SPATA13 APC
11 reproductive system MP:0005389 9.5 APC APC2 AXIN1 AXIN2 CDH1 CTNNB1
12 skeleton MP:0005390 9.17 AMER1 APC AXIN1 AXIN2 CTNNB1 GSK3B

Drugs & Therapeutics for Adenomatous Polyposis Coli

Drugs for Adenomatous Polyposis Coli (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 84)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Erythromycin Approved, Vet_approved Phase 4 114-07-8 12560
2
Celecoxib Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 169590-42-5 2662
3 Anti-Bacterial Agents Phase 4,Phase 2,Phase 1
4 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
5 Erythromycin Estolate Phase 4
6 Erythromycin Ethylsuccinate Phase 4
7 Erythromycin stearate Phase 4
8 Gastrointestinal Agents Phase 4,Phase 2,Phase 3
9 Analgesics Phase 4,Phase 2,Phase 3,Phase 1
10 Analgesics, Non-Narcotic Phase 4,Phase 2,Phase 3,Phase 1
11 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3,Phase 1
12 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 2,Phase 3,Phase 1
13 Antirheumatic Agents Phase 4,Phase 2,Phase 3,Phase 1
14 Cyclooxygenase 2 Inhibitors Phase 4,Phase 2,Phase 3,Phase 1
15 Cyclooxygenase Inhibitors Phase 4,Phase 2,Phase 3,Phase 1
16 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1
17
Ursodeoxycholic acid Approved, Investigational Phase 2, Phase 3 128-13-2 31401
18
Sulindac Approved Phase 3,Phase 2 38194-50-2 5352 1548887
19
Loperamide Approved Phase 3 53179-11-6 3955
20 Dolutegravir Approved Phase 3 1051375-16-6 54726191
21 Cholagogues and Choleretics Phase 2, Phase 3
22 Antiviral Agents Phase 3
23 Antidiarrheals Phase 3
24 Antibodies Phase 3
25 Immunoglobulins Phase 3
26 Antiparasitic Agents Phase 3,Phase 2
27 Antiprotozoal Agents Phase 3,Phase 2
28 Protective Agents Phase 2, Phase 3
29 Antibodies, Monoclonal Phase 3
30 Anti-HIV Agents Phase 3
31 Anti-Retroviral Agents Phase 3
32 HIV Integrase Inhibitors Phase 3
33 Integrase Inhibitors Phase 3
34 Cola Nutraceutical Phase 2, Phase 3, Phase 1
35 Omega 3 Fatty Acid Nutraceutical Phase 2, Phase 3
36
Ornithine Nutraceutical Phase 3,Phase 2 3184-13-2 6262 389
37
Metformin Approved Phase 2 657-24-9 14219 4091
38
Everolimus Approved Phase 2,Phase 1 159351-69-6 6442177
39
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1 22916-47-8 4189
40
Sirolimus Approved, Investigational Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
41
Inulin Approved, Nutraceutical Phase 2 9005-80-5 24763
42
Vitamin A Approved, Nutraceutical, Vet_approved Phase 2 11103-57-4, 68-26-8 445354
43 Hypoglycemic Agents Phase 2
44
Erlotinib Hydrochloride Phase 2 183319-69-9 176871
45 Protein Kinase Inhibitors Phase 2
46 Retinol palmitate Phase 2
47
Curcumin Phase 2 458-37-7 969516
48 Turmeric extract Phase 2
49 Antibiotics, Antitubercular Phase 2,Phase 1
50 Antifungal Agents Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 85)
id Name Status NCT ID Phase
1 Erythromycin Treatment for Readthrough of APC Gene Stop Codon Mutations in Familial Adenomatous Polyposis Unknown status NCT02175914 Phase 4
2 Erythromycin Treatment for Readthrough of APC Gene Stop Codon Mutation in Familial Adenomatous Polyposis-minors' Adjusted Version Not yet recruiting NCT02354560 Phase 4
3 A Study of Rofecoxib in Familial Adenomatous Polyposis (FAP) Terminated NCT00140894 Phase 4
4 Observational Familial Adenomatous Polyposis Registry Study In Patients Receiving Celecoxib Compared to Control Patients Terminated NCT00151476 Phase 4
5 Ursodeoxycholic Acid in the Treatment of Duodenal Adenomas in Familial Adenomatous Polyposis (FAP) Patients Unknown status NCT00134758 Phase 2, Phase 3
6 Chemoprevention Trial in Familial Adenomatous Polyposis (FAP) Coli Using EPA Completed NCT00510692 Phase 2, Phase 3
7 Prevention of Progression of Duodenal Adenomas in Patients With Familial Adenomatous Polyposis Completed NCT00808743 Phase 2, Phase 3
8 Celecoxib to Prevent Colorectal Cancer in Patients Who Have Undergone Surgery to Remove Polyps Completed NCT00005094 Phase 3
9 Clinical Approaches to Ileal Pouch Dysfunction Completed NCT00293553 Phase 3
10 Australian Clinical Study of the Apnex Medical HGNS System to Treat Obstructive Sleep Apnea Completed NCT01186926 Phase 2, Phase 3
11 Use of Post Operative Loperamide in Colorectal Patients After Diverting Ileostomies Recruiting NCT02263365 Phase 3
12 Trial of Eflornithine Plus Sulindac in Patients With Familial Adenomatous Polyposis (FAP) Active, not recruiting NCT01483144 Phase 3
13 Compassionate Use of Ibalizumab for the Treatment of HIV Infection No longer available NCT02028819 Phase 3
14 Trial In Pediatric Patients With Familial Adenomatous Polyposis (FAP) Terminated NCT00585312 Phase 3
15 Coxib-inhibition of Duodenal Polyp Growth in FAP Terminated NCT00844727 Phase 2, Phase 3
16 A Trial of Low Dose Sulindac Combined With Eflornithine in Patients With Familial Adenomatous Polyposis (FAP) Withdrawn NCT01245816 Phase 3
17 Exisulind in Preventing Polyps in Patients With Familial Adenomatous Polyposis Withdrawn NCT00026468 Phase 2, Phase 3
18 Influence of Sulindac and Probiotics on the Development of Pouch Adenomas in Patients With Familial Adenomatous Polyposis Unknown status NCT00319007 Phase 2
19 The Chemopreventive Effect of Metformin in Patients With Familial Adenomatous Polyposis: Double Blinded Randomized Controlled Study Unknown status NCT01725490 Phase 2
20 Treatment for Presumed Ocular Histoplasmosis Unknown status NCT01790893 Phase 1, Phase 2
21 A Clinical Trial of COX and EGFR Inhibition in Familial Polyposis Patients Completed NCT01187901 Phase 2
22 Curcumin in Treating Patients With Familial Adenomatous Polyposis Completed NCT00641147 Phase 2
23 Sirolimus and Familial Adenomatous Polyposis (FAP) Recruiting NCT03095703 Phase 2
24 A Pilot Study Evaluating the Use of mTor Inhibitor Sirolimus in Children and Young Adults With Desmoid-Type Fibromatosis Recruiting NCT01265030 Phase 1, Phase 2
25 MLE4901 vs. Placebo for the Treatment of PCOS Recruiting NCT02865915 Phase 2
26 Molecular Targeting of 15-Lipoxygenase-1 (15-LOX-1) for Apoptosis Induction in Human Colorectal Cancers Active, not recruiting NCT00503035 Phase 2
27 Erlotinib Hydrochloride in Reducing Duodenal Polyp Burden in Patients With Familial Adenomatous Polyposis at Risk of Developing Colon Cancer Not yet recruiting NCT02961374 Phase 2
28 Turmeric Supplementation on Polyp Number and Size in Patients With Familial Adenomatous Polyposis. Not yet recruiting NCT03061591 Phase 2
29 Celecoxib With or Without Eflornithine in Preventing Colorectal Cancer in Patients With Familial Adenomatous Polyposis Terminated NCT00033371 Phase 2
30 Outpatient Neutropenic Diet Study Terminated NCT00947648 Phase 2
31 Use of Curcumin in the Lower Gastrointestinal Tract in Familial Adenomatous Polyposis Patients Withdrawn NCT00248053 Phase 2
32 Molecular Fluorescence Endoscopy in Patients With Familial Adenomatous Polyposis, Using Bevacizumab-IRDye800CW Completed NCT02113202 Phase 1
33 Lyophilized Black Raspberries in Adults With Familial Adenomatous Polyposis (FAP) Completed NCT00770991 Phase 1
34 Celecoxib in Preventing Colorectal Cancer in Young Patients With a Genetic Predisposition for Familial Adenomatous Polyposis Completed NCT00685568 Phase 1
35 A Pilot Open-Label Crossover Bioavailability Study of Celecoxib in Healthy Volunteers Completed NCT00813241 Phase 1
36 Study of Biochemical Markers to Determine the Acetylsalicylic Acid Chemopreventive Effect Through Antiplatelet Action Completed NCT02060396 Phase 1
37 Adenoma Detection Rate:NBI, AFI, Chromoscopic or Standard Endoscopy Unknown status NCT00253812
38 Chemoprevention of Gastric Cancer by Intervention With Helicobacter Pylori and Cyclooxygenase Pathway Unknown status NCT00498134
39 Collecting Information From Patients and Family Members With Hereditary Colorectal Cancer Syndromes or Who Are at High Risk of Developing Colorectal Cancer Unknown status NCT00675636
40 Is Diverting Ileostomy Necessary in Stapled Ileoanal Pouch? Completed NCT01173250
41 A Cohort Study of Patients Treated With Brachytherapy for Selected Desmoid Patients in Gardner Syndrome Completed NCT01286662
42 Dual Focus NBI and pCLE in FAP Related Duodenal Adenoma Completed NCT02162173
43 Genetic Analysis of Hereditary Prostate Cancer Completed NCT00001469
44 Alcohol Intake, Alcohol Metabolizing Enzymes Gene Polymorphisms and the Risk of Colorectal Cancer Completed NCT03155542
45 Endoscopic Papillectomy for Early Ampullary Tumors: Long-term Results of the First Large Multicenter Prospective Study Completed NCT01764503
46 Oligogenic Determinism of Colorectal Cancer Completed NCT01057953
47 Single Incision Laparoscopic Surgery in Treating Patients With Colorectal Disease Completed NCT01656746
48 Effects of Omega-3 Fatty Acids on Markers of Inflammation Completed NCT01129050
49 Ingenio Device Algorithm Study Completed NCT01441583
50 Effects of Raw Versus Other Milk Sources on Lactose Digestion Completed NCT01129791

Search NIH Clinical Center for Adenomatous Polyposis Coli

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Genetic Tests for Adenomatous Polyposis Coli

Genetic tests related to Adenomatous Polyposis Coli:

id Genetic test Affiliating Genes
1 Familial Adenomatous Polyposis 1 29
2 Gardner Syndrome 29 24 APC
3 Brain Tumor-Polyposis Syndrome 2 29

Anatomical Context for Adenomatous Polyposis Coli

MalaCards organs/tissues related to Adenomatous Polyposis Coli:

39
Colon, Skin, Thyroid, Brain, Liver, Bone, Adrenal Gland

Publications for Adenomatous Polyposis Coli

Articles related to Adenomatous Polyposis Coli:

(show top 50) (show all 305)
id Title Authors Year
1
Does adenomatous polyposis coli gene promoter 1A methylation increase non-small cell lung cancer risk? A meta-analysis. ( 28497891 )
2017
2
A metabolic switch controls intestinal differentiation downstream of Adenomatous polyposis coli (APC). ( 28397687 )
2017
3
Extracolonic cancer risk in Dutch patients with APC (adenomatous polyposis coli)-associated polyposis. ( 28490611 )
2017
4
Insulin signaling regulates a functional interaction between Adenomatous Polyposis Coli (APC) and cytoplasmic dynein. ( 28057765 )
2017
5
Association between Hepatitis C Virus Infection, p53 Phenotypes, and Gene Variants of Adenomatous Polyposis Coli in Hepatocellular Carcinomas. ( 28203651 )
2016
6
Adenomatous polyposis coli regulates radial axonal sorting and myelination in the PNS. ( 27226321 )
2016
7
Characterization of Adenomatous Polyposis Coli Protein Dynamics and Localization at the Centrosome. ( 27144584 )
2016
8
miR-582-5P induces colorectal cancer cell proliferation by targeting adenomatous polyposis coli. ( 27595705 )
2016
9
Cribriform morular variant of papillary thyroid carcinoma: Cytomorphology, differential diagnosis and diagnostic implications in patients with adenomatous polyposis coli. ( 28028343 )
2016
10
Tumour Suppressor Adenomatous Polyposis Coli (APC) localisation is regulated by both Kinesin-1 and Kinesin-2. ( 27272132 )
2016
11
Copy number of the Adenomatous Polyposis Coli gene is not always neutral in sporadic colorectal cancers with loss of heterozygosity for the gene. ( 26970738 )
2016
12
A novel pathogenic large germline deletion in adenomatous polyposis coli gene in a Chinese family with familial adenomatous polyposis. ( 27391059 )
2016
13
Inactivation of Adenomatous Polyposis Coli Reduces Bile Acid/Farnesoid X Receptor Expression through Fxr gene CpG Methylation in Mouse Colon Tumors and Human Colon Cancer Cells. ( 26609171 )
2016
14
Selective targeting of mutant adenomatous polyposis coli (APC) in colorectal cancer. ( 27798265 )
2016
15
Adenomatous polyposis coli genotype-dependent toll-like receptor 4 activity in colon cancer. ( 26760960 )
2016
16
Deep vein thrombosis in a patient of adenomatous polyposis coli treated successfully with aspirin: A case report. ( 27386068 )
2016
17
ABT-888 and quinacrine induced apoptosis in metastatic breast cancer stem cells by inhibiting base excision repair via adenomatous polyposis coli. ( 27334689 )
2016
18
Analysing the mutational status of adenomatous polyposis coli (APC) gene in breast cancer. ( 27028212 )
2016
19
Adenomatous polyposis coli (APC) regulates miR17-92 cluster through I^-catenin pathway in colorectal cancer. ( 26804172 )
2016
20
MicroRNA-663 activates the canonical Wnt signaling through the adenomatous polyposis coli suppression. ( 26028359 )
2015
21
Adenomatous polyposis coli mutants dominantly activate Hsf1-dependent cell stress pathways through inhibition of microtubule dynamics. ( 26320184 )
2015
22
Association of CD24 and the adenomatous polyposis coli gene polymorphisms with oral lichen planus. ( 26187149 )
2015
23
Tissue-Specific Effects of Reduced I^-catenin Expression on Adenomatous Polyposis Coli Mutation-Instigated Tumorigenesis in Mouse Colon and Ovarian Epithelium. ( 26528816 )
2015
24
Adenomatous Polyposis Coli Protein Deletion in Efferent Olivocochlear Neurons Perturbs Afferent Synaptic Maturation and Reduces the Dynamic Range of Hearing. ( 26085645 )
2015
25
Adenomatous polyposis coli (APC)-induced apoptosis of HT29 colorectal cancer cells depends on mitochondrial oxidative metabolism. ( 26004395 )
2015
26
Mesenchymal adenomatous polyposis coli plays critical and diverse roles in regulating lung development. ( 26092405 )
2015
27
Concurrent Hepsin overexpression and adenomatous polyposis coli deletion causes invasive prostate carcinoma in mice. ( 26139199 )
2015
28
High-resolution Melting Analysis for Gene Scanning of Adenomatous Polyposis Coli (APC) Gene With Oral Squamous Cell Carcinoma Samples. ( 26447891 )
2015
29
Molecular mechanism of adenomatous polyposis coli-induced blockade of base excision repair pathway in colorectal carcinogenesis. ( 26334567 )
2015
30
Expression and mutation pattern of I^-catenin and adenomatous polyposis coli in colorectal cancer patients. ( 25660336 )
2015
31
Adenomatous Polyposis Coli Mutation Leads to Myopia Development in Mice. ( 26495845 )
2015
32
A novel pathogenic germline mutation in the adenomatous polyposis coli gene in a Chinese family with familial adenomatous coli. ( 26311738 )
2015
33
Residual rectal mucosa after stapled vs. handsewn ileal J-pouch-anal anastomosis in patients with familial adenomatous polyposis coli (FAP)--a critical issue. ( 25586093 )
2015
34
Two Chinese pedigrees for adenomatous polyposis coli: new mutations at codon 1309 and predisposition to phenotypic variations. ( 24664542 )
2014
35
Low-grade neuroendocrine tumors arising in intestinal adenomas: evidence for alterations in the adenomatous polyposis coli/I^-catenin pathway. ( 25149552 )
2014
36
Adenomatous polyposis coli (APC) membrane recruitment 3, a member of the APC membrane recruitment family of APC-binding proteins, is a positive regulator of Wnt-I^-catenin signalling. ( 24251807 )
2014
37
Early postoperative complications after stapled vs handsewn restorative proctocolectomy with ileal pouch-anal anastomosis in 148 patients with familial adenomatous polyposis coli: a matched-pair analysis. ( 23941307 )
2014
38
different Roles for the axin interactions with the SAMP versus the second twenty amino acid repeat of adenomatous polyposis coli. ( 24722208 )
2014
39
Aspirin augments the expression of Adenomatous Polyposis Coli protein by suppression of IKKI^. ( 24613833 )
2014
40
The effects of genistein and daidzein on cell proliferation kinetics in HT29 colon cancer cells: the expression of CTNNBIP1 (I^-catenin), APC (adenomatous polyposis coli) and BIRC5 (survivin). ( 24390805 )
2014
41
5-Fluorouracil mediated anti-cancer activity in colon cancer cells is through the induction of Adenomatous Polyposis Coli: Implication of the long-patch base excision repair pathway. ( 25460919 )
2014
42
Adenomatous polyposis coli gene large deletions in Iranian patients with familial adenomatous polyposis. ( 25494137 )
2014
43
Minimal access laparoscopic surgery for treatment of ulcerative colitis and familial adenomatous polyposis coli in children and adolescents. ( 25247476 )
2014
44
N-terminal truncation mutations of adenomatous polyposis coli are associated with primary cilia defects. ( 25150829 )
2014
45
Anal transitional zone neoplasia in patients with familial adenomatous polyposis coli syndrome. ( 23739184 )
2013
46
Ultrasensitive detection of unknown colon cancer-initiating mutations using the example of the Adenomatous polyposis coli gene. ( 24005794 )
2013
47
Desmoid tumour biology in patients with familial adenomatous polyposis coli. ( 23334997 )
2013
48
miR-106b downregulates adenomatous polyposis coli and promotes cell proliferation in human hepatocellular carcinoma. ( 23087084 )
2013
49
Adenomatous polyposis coli gene involvement in ileal enterochromaffin cell neuroendocrine neoplasms. ( 24139208 )
2013
50
Adenomatous polyposis coli-mediated accumulation of abasic DNA lesions lead to cigarette smoke condensate-induced neoplastic transformation of normal breast epithelial cells. ( 23555190 )
2013

Variations for Adenomatous Polyposis Coli

UniProtKB/Swiss-Prot genetic disease variations for Adenomatous Polyposis Coli:

66 (show all 11)
id Symbol AA change Variation ID SNP ID
1 APC p.Ser171Ile VAR_005032
2 APC p.Arg414Cys VAR_005033 rs137854567
3 APC p.Ser784Thr VAR_005034
4 APC p.Glu911Gly VAR_005038
5 APC p.Pro1176Leu VAR_005044
6 APC p.Thr1313Ala VAR_005051 rs863225349
7 APC p.Arg1348Trp VAR_005053
8 APC p.Ser2621Cys VAR_005056 rs72541816
9 APC p.Leu2839Phe VAR_005057
10 APC p.Ser722Gly VAR_009614
11 APC p.Ala1184Pro VAR_009616

ClinVar genetic disease variations for Adenomatous Polyposis Coli:

6 (show top 50) (show all 182)
id Gene Variation Type Significance SNP ID Assembly Location
1 APC NM_000038.5(APC): c.730_731delAG (p.Arg244Valfs) deletion Pathogenic rs387906228 GRCh37 Chromosome 5, 112136976: 112136977
2 APC NM_000038.5(APC): c.1369delT (p.Ser457Hisfs) deletion Pathogenic rs387906229 GRCh37 Chromosome 5, 112157649: 112157649
3 APC NM_000038.5(APC): c.1500T> G (p.Tyr500Ter) single nucleotide variant Pathogenic rs387906230 GRCh37 Chromosome 5, 112162896: 112162896
4 APC NM_000038.5(APC): c.904C> T (p.Arg302Ter) single nucleotide variant Pathogenic rs137854568 GRCh37 Chromosome 5, 112151261: 112151261
5 APC NM_000038.5(APC): c.839C> G (p.Ser280Ter) single nucleotide variant Pathogenic rs137854569 GRCh37 Chromosome 5, 112151196: 112151196
6 APC NM_000038.5(APC): c.2138C> G (p.Ser713Ter) single nucleotide variant Pathogenic rs137854570 GRCh37 Chromosome 5, 112173429: 112173429
7 APC NM_000038.5(APC): c.4012C> T (p.Gln1338Ter) single nucleotide variant Pathogenic/Likely pathogenic rs121913327 GRCh37 Chromosome 5, 112175303: 112175303
8 APC NM_000038.5(APC): c.509_512delATAG (p.Asp170Valfs) deletion Pathogenic rs387906231 GRCh37 Chromosome 5, 112111412: 112111415
9 APC NM_000038.5(APC): c.1069dupA (p.Ile357Asnfs) duplication Pathogenic rs387906232 GRCh37 Chromosome 5, 112154798: 112154798
10 APC NM_000038.5(APC): c.1621C> T (p.Gln541Ter) single nucleotide variant Pathogenic rs137854572 GRCh37 Chromosome 5, 112163698: 112163698
11 APC NM_000038.5(APC): c.1660C> T (p.Arg554Ter) single nucleotide variant Pathogenic rs137854573 GRCh37 Chromosome 5, 112164586: 112164586
12 APC NM_000038.5(APC): c.1690C> T (p.Arg564Ter) single nucleotide variant Pathogenic rs137854574 GRCh37 Chromosome 5, 112164616: 112164616
13 APC NM_000038.5(APC): c.1885_1886insA (p.Leu629Tyrfs) insertion Pathogenic rs387906233 GRCh37 Chromosome 5, 112170789: 112170790
14 APC NM_000038.5(APC): c.2805C> A (p.Tyr935Ter) single nucleotide variant Pathogenic rs137854575 GRCh37 Chromosome 5, 112174096: 112174096
15 APC NM_000038.5(APC): c.4393_4394delAG (p.Ser1465Trpfs) deletion Pathogenic rs387906234 GRCh37 Chromosome 5, 112175684: 112175685
16 APC NM_000038.5(APC): c.4391_4394delAGAG (p.Glu1464Valfs) deletion Pathogenic rs387906235 GRCh37 Chromosome 5, 112175682: 112175685
17 APC NM_000038.5(APC): c.470G> A (p.Trp157Ter) single nucleotide variant Pathogenic rs137854576 GRCh37 Chromosome 5, 112111373: 112111373
18 APC NM_000038.5(APC): c.643C> T (p.Gln215Ter) single nucleotide variant Pathogenic rs137854577 GRCh37 Chromosome 5, 112116598: 112116598
19 APC NC_000005.10: g.112836913_112908314del71402 deletion Pathogenic GRCh37 Chromosome 5, 112172610: 112244011
20 APC NM_000038.5(APC): c.3927_3931delAAAGA (p.Glu1309Aspfs) deletion Pathogenic rs121913224 GRCh37 Chromosome 5, 112175218: 112175222
21 APC NM_000038.5(APC): c.5942delA (p.Asn1981Ilefs) deletion Pathogenic rs397509433 GRCh37 Chromosome 5, 112177233: 112177233
22 APC NM_000038.5(APC): c.5582_5585delCTTT (p.Ser1861Terfs) deletion Pathogenic rs587776520 GRCh38 Chromosome 5, 112841176: 112841179
23 APC NM_000038.5(APC): c.4611_4612delAG (p.Glu1538Ilefs) deletion Pathogenic rs387906236 GRCh37 Chromosome 5, 112175902: 112175903
24 APC NM_000038.5(APC): c.1495C> T (p.Arg499Ter) single nucleotide variant Pathogenic rs137854580 GRCh37 Chromosome 5, 112162891: 112162891
25 APC APC, TYR486TER single nucleotide variant Pathogenic
26 APC NM_000038.5(APC): c.1311_1312+1delAAG deletion Pathogenic rs397514030 GRCh37 Chromosome 5, 112155040: 112155042
27 APC NM_000038.5(APC): c.1098_1099delCT (p.Ser367Cysfs) deletion Pathogenic rs387906237 GRCh37 Chromosome 5, 112154827: 112154828
28 APC NM_000038.5(APC): c.1192_1193delAA (p.Lys398Glufs) deletion Pathogenic rs387906238 GRCh37 Chromosome 5, 112154921: 112154922
29 APC NM_000038.5(APC): c.937_938delGA (p.Glu313Asnfs) deletion Pathogenic rs387906239 GRCh37 Chromosome 5, 112154666: 112154667
30 APC NM_000038.5(APC): c.2093T> A (p.Leu698Ter) single nucleotide variant Pathogenic rs137854582 GRCh37 Chromosome 5, 112173384: 112173384
31 APC APC deletion deletion Pathogenic GRCh38 Chromosome 5, 112707504: 112846240
32 APC NM_000038.5(APC): c.423-1G> A single nucleotide variant Pathogenic rs397514031 GRCh37 Chromosome 5, 112111325: 112111325
33 APC APC, 11-BP INS, NT1060 insertion Pathogenic
34 APC NM_000038.5(APC): c.622C> T (p.Gln208Ter) single nucleotide variant Pathogenic rs137854583 GRCh37 Chromosome 5, 112116577: 112116577
35 APC NG_008481.4: g.(?_150033)_(158719_?)del deletion Pathogenic GRCh38 Chromosome 5, 112837553: 112846239
36 APC APC, 5-BP DEL, NT3221 deletion Pathogenic
37 APC NM_000038.5(APC): c.1917dupA (p.Arg640Thrfs) duplication Likely pathogenic rs397515732 GRCh37 Chromosome 5, 112170821: 112170821
38 APC NM_000038.5(APC): c.3162delC (p.His1054Glnfs) deletion Pathogenic rs397515733 GRCh37 Chromosome 5, 112174453: 112174453
39 APC NM_000038.5(APC): c.694C> T (p.Arg232Ter) single nucleotide variant Pathogenic rs397515734 GRCh37 Chromosome 5, 112128191: 112128191
40 APC NM_000038.5(APC): c.896_897delCT (p.Ser299Cysfs) deletion Pathogenic rs397515735 GRCh37 Chromosome 5, 112151253: 112151254
41 APC NM_000038.5(APC): c.3183_3187delACAAA (p.Gln1062Terfs) deletion Pathogenic rs587779352 GRCh37 Chromosome 5, 112174474: 112174478
42 APC NM_000038.5(APC): c.3202_3205delTCAA (p.Ser1068Glyfs) deletion Pathogenic rs587779353 GRCh37 Chromosome 5, 112174493: 112174496
43 APC NM_000038.5(APC): c.1659G> A (p.Trp553Ter) single nucleotide variant Pathogenic rs398123116 GRCh37 Chromosome 5, 112164585: 112164585
44 APC NM_000038.5(APC): c.2365C> T (p.Gln789Ter) single nucleotide variant Pathogenic rs398123117 GRCh37 Chromosome 5, 112173656: 112173656
45 APC NM_000038.5(APC): c.2547_2550delTAGA (p.Asp849Glufs) deletion Pathogenic rs398123118 GRCh37 Chromosome 5, 112173838: 112173841
46 APC NM_000038.5(APC): c.2731G> T (p.Glu911Ter) single nucleotide variant Pathogenic rs398123119 GRCh37 Chromosome 5, 112174022: 112174022
47 APC NM_000038.5(APC): c.2805delC (p.Tyr935Terfs) deletion Pathogenic rs398123120 GRCh37 Chromosome 5, 112174096: 112174096
48 APC NM_000038.5(APC): c.3982C> T (p.Gln1328Ter) single nucleotide variant Pathogenic rs398123121 GRCh37 Chromosome 5, 112175273: 112175273
49 APC NM_000038.5(APC): c.4473dupT (p.Ala1492Cysfs) duplication Pathogenic rs398123122 GRCh37 Chromosome 5, 112175764: 112175764
50 APC NM_000038.5(APC): c.1213C> T (p.Arg405Ter) single nucleotide variant Pathogenic rs587779780 GRCh38 Chromosome 5, 112819245: 112819245

Expression for Adenomatous Polyposis Coli

Search GEO for disease gene expression data for Adenomatous Polyposis Coli.

Pathways for Adenomatous Polyposis Coli

Pathways related to Adenomatous Polyposis Coli according to GeneCards Suite gene sharing:

(show all 48)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.61 AMER1 APC AXIN1 CDH1 CTNNB1 GSK3B
2
Show member pathways
13.01 APC APC2 AXIN1 AXIN2 CDH1 CTNNB1
3
Show member pathways
12.9 AMER1 APC AXIN1 AXIN2 CTNNB1 GSK3B
4
Show member pathways
12.69 APC CDH1 CTNNB1 GSK3B
5
Show member pathways
12.58 AMER1 APC AXIN1 AXIN2 CTNNB1 GSK3B
6 12.52 APC APC2 AXIN1 AXIN2 CDH1 CTNNB1
7
Show member pathways
12.48 CDH1 CTNNB1 GSK3B MYC
8
Show member pathways
12.48 APC APC2 AXIN1 AXIN2 CTNNB1 GSK3B
9 12.46 APC AXIN1 CDH1 CTNNB1 GSK3B MYC
10
Show member pathways
12.45 APC AXIN1 AXIN2 CTNNB1
11
Show member pathways
12.44 APC AXIN1 AXIN2 GSK3B
12 12.43 APC APC2 CTNNB1 GSK3B MYC
13
Show member pathways
12.41 APC AXIN1 CTNNB1 GSK3B
14
Show member pathways
12.39 APC APC2 AXIN1 AXIN2 CTNNB1 GSK3B
15
Show member pathways
12.35 AXIN1 AXIN2 CTNNB1 GSK3B
16 12.32 APC CDH1 GSK3B MYC
17
Show member pathways
12.25 APC CDH1 CTNNB1 GSK3B
18
Show member pathways
12.25 APC AXIN1 AXIN2 CTNNB1 GSK3B
19 12.25 AMER1 APC AXIN1 AXIN2 CTNNB1 GSK3B
20 12.16 APC AXIN1 CDH1 CTNNB1 GSK3B
21 12.15 APC AXIN2 CDH1 CTNNB1 GSK3B MYC
22 12.08 APC AXIN1 CDH1 CTNNB1 GSK3B
23 12.06 CDH1 CTNNB1 MYC
24 12.03 APC AXIN1 CTNNB1 GSK3B MYC
25 12.02 APC CTNNB1 GSK3B
26 12.01 APC AXIN1 CTNNB1 GSK3B MYC
27 11.96 APC AXIN1 CTNNB1 GSK3B
28 11.94 APC APC2 AXIN1 AXIN2 CTNNB1 GSK3B
29
Show member pathways
11.93 APC CDH1 CTNNB1
30 11.92 CTNNB1 GSK3B MYC
31
Show member pathways
11.91 APC APC2 AXIN1 AXIN2 CDH1 CTNNB1
32 11.85 AXIN1 AXIN2 CDH1 CTNNB1 GSK3B MYC
33 11.82 APC AXIN2 CDH1 CTNNB1 MYC
34 11.73 APC AXIN1 CTNNB1 GSK3B MYC
35 11.46 APC AXIN1 CTNNB1 GSK3B MYC
36 11.41 APC APC2 AXIN1 AXIN2 CDH1 CTNNB1
37 11.4 CDH1 CTNNB1 MAPRE1 MAPRE2 MAPRE3
38 11.36 APC AXIN1 AXIN2 CTNNB1 GSK3B MYC
39 11.34 AXIN1 CTNNB1 MAPRE1
40 11.3 APC AXIN1 CTNNB1
41 11.28 CDH1 CTNNB1 MYC
42 11.22 APC AXIN2 CTNNB1 GSK3B
43 11.18 APC SPATA13
44 11.15 AXIN1 GSK3B MYC
45 11.09 CDH1 CTNNB1
47 11.03 APC AXIN1 CTNNB1 GSK3B
48 10.79 CDH1 CTNNB1

GO Terms for Adenomatous Polyposis Coli

Cellular components related to Adenomatous Polyposis Coli according to GeneCards Suite gene sharing:

(show all 16)
id Name GO ID Score Top Affiliating Genes
1 centrosome GO:0005813 9.89 APC AXIN2 CTNNB1 GSK3B MAPRE1
2 perinuclear region of cytoplasm GO:0048471 9.88 APC APC2 AXIN1 CDH1 CTNNB1 GSK3B
3 microtubule GO:0005874 9.83 APC APC2 MAPRE1 MAPRE2 MAPRE3
4 lamellipodium GO:0030027 9.78 APC CDH1 CTNNB1 SPATA13
5 microtubule cytoskeleton GO:0015630 9.76 APC2 MAPRE1 MAPRE2 MAPRE3
6 cell-cell adherens junction GO:0005913 9.69 APC CDH1 CTNNB1
7 apical junction complex GO:0043296 9.56 CDH1 CTNNB1
8 cell projection membrane GO:0031253 9.54 CTNNB1 MAPRE1
9 microtubule plus-end GO:0035371 9.54 MAPRE1 MAPRE2 MAPRE3
10 flotillin complex GO:0016600 9.52 CDH1 CTNNB1
11 lateral plasma membrane GO:0016328 9.46 APC AXIN1 CDH1 CTNNB1
12 Wnt signalosome GO:1990909 9.43 APC CTNNB1 GSK3B
13 catenin complex GO:0016342 9.26 APC APC2 CDH1 CTNNB1
14 beta-catenin destruction complex GO:0030877 9.02 APC AXIN1 AXIN2 CTNNB1 GSK3B
15 cytoplasm GO:0005737 10.13 AMER1 APC APC2 AXIN1 AXIN2 CDH1
16 cytoskeleton GO:0005856 10.02 APC APC2 CTNNB1 MAPRE1 MAPRE2 MAPRE3

Biological processes related to Adenomatous Polyposis Coli according to GeneCards Suite gene sharing:

(show all 23)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription, DNA-templated GO:0045893 9.96 AXIN1 CDH1 CTNNB1 MAPRE3 MYC
2 protein deubiquitination GO:0016579 9.87 APC AXIN1 AXIN2 MYC
3 cell proliferation GO:0008283 9.85 AXIN2 CTNNB1 MAPRE1 MAPRE2 MYC
4 positive regulation of canonical Wnt signaling pathway GO:0090263 9.77 AMER1 AXIN1 AXIN2
5 proteasome-mediated ubiquitin-dependent protein catabolic process GO:0043161 9.77 AMER1 APC AXIN1 CTNNB1 GSK3B
6 negative regulation of canonical Wnt signaling pathway GO:0090090 9.73 AMER1 APC APC2 AXIN1 AXIN2 GSK3B
7 canonical Wnt signaling pathway GO:0060070 9.72 APC AXIN1 CTNNB1 GSK3B MYC
8 positive regulation of protein catabolic process GO:0045732 9.71 APC AXIN1 GSK3B
9 negative regulation of Wnt signaling pathway GO:0030178 9.7 APC APC2 AXIN1
10 Wnt signaling pathway GO:0016055 9.7 AMER1 APC APC2 AXIN1 AXIN2 CTNNB1
11 beta-catenin-TCF complex assembly GO:1904837 9.65 AXIN2 CTNNB1 MYC
12 positive regulation of peptidyl-threonine phosphorylation GO:0010800 9.61 AXIN1 GSK3B
13 positive regulation of mesenchymal cell proliferation GO:0002053 9.61 CTNNB1 MYC
14 entry of bacterium into host cell GO:0035635 9.59 CDH1 CTNNB1
15 regulation of microtubule-based process GO:0032886 9.58 APC GSK3B
16 negative regulation of catenin import into nucleus GO:0035414 9.58 APC2 AXIN2
17 protein localization to microtubule GO:0035372 9.55 GSK3B MAPRE1
18 cellular response to indole-3-methanol GO:0071681 9.51 CDH1 CTNNB1
19 re-entry into mitotic cell cycle GO:0000320 9.49 GSK3B MYC
20 regulation of centromeric sister chromatid cohesion GO:0070602 9.43 AXIN2 CTNNB1
21 positive regulation of microtubule plus-end binding GO:1903033 9.4 MAPRE1 MAPRE3
22 beta-catenin destruction complex assembly GO:1904885 9.26 AMER1 APC AXIN1 GSK3B
23 beta-catenin destruction complex disassembly GO:1904886 9.02 AMER1 APC AXIN1 CTNNB1 GSK3B

Molecular functions related to Adenomatous Polyposis Coli according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.85 APC AXIN1 MAPRE1 MAPRE2 MAPRE3
2 protein kinase binding GO:0019901 9.78 APC AXIN1 CTNNB1 GSK3B
3 ubiquitin protein ligase binding GO:0031625 9.71 APC AXIN1 AXIN2 GSK3B
4 cadherin binding GO:0045296 9.67 APC CDH1 CTNNB1 MAPRE1
5 microtubule binding GO:0008017 9.55 APC APC2 MAPRE1 MAPRE2 MAPRE3
6 microtubule plus-end binding GO:0051010 9.43 APC MAPRE1
7 gamma-catenin binding GO:0045295 9.32 APC CDH1
8 beta-catenin binding GO:0008013 9.17 AMER1 APC APC2 AXIN1 AXIN2 CDH1
9 I-SMAD binding GO:0070411 9.13 AXIN1 AXIN2 CTNNB1
10 protein binding GO:0005515 10.07 AMER1 APC APC2 AXIN1 AXIN2 CDH1

Sources for Adenomatous Polyposis Coli

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....